GlassScriptPhysician profile
Brittany Slone
NPI 1366904302
$1,650.49
in general payments reported to CMS, 2019-2025
24 companies · $576 in 2025
The $576 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $301 · 2023: $207 · 2024: $401 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.57 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $205.49 | 2021-2022 | |
| Axsome Therapeutics, INC. | $154.19 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $134.44 | 2021-2024 | Xarelto |
| Abbvie INC. | $128.65 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.33 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $78.50 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $75.13 | 2025 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $65.96 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $45.98 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $45.06 | 2022-2025 | Vpriv |
| Biohaven Pharmaceutical Holding Company LTD. | $40.72 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.97 | 2022-2023 | Quviviq |
| Amgen INC. | $35.94 | 2021-2024 | Repatha, Otezla |
| Medicure Pharma INC. | $25.66 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.16 | 2021-2022 | |
| Lundbeck LLC | $21.64 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $19.06 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $15.89 | 2024 | |
| Abbott Laboratories | $15.62 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $14.73 | 2024 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2024 | Xifaxan |
| Genentech USA, INC. | $14.00 | 2022 | |
| Exact Sciences Corporation | $13.44 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Slone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.